

## Accepted Manuscript

Title: The coming of age of engineered multivalent antibodies

Author: Natalia Nuñez-Prado Marta Compte Seandean  
Harwood Ana Álvarez-Méndez Simon Lykkemark Laura Sanz  
Luis Álvarez-Vallina



PII: S1359-6446(15)00098-7  
DOI: <http://dx.doi.org/doi:10.1016/j.drudis.2015.02.013>  
Reference: DRUDIS 1589

To appear in:

Received date: 16-11-2014  
Revised date: 14-2-2015  
Accepted date: 27-2-2015

Please cite this article as: Nuñez-Prado, N., Compte, M., Harwood, S., Álvarez-Méndez, A., Lykkemark, S., Sanz, L., Álvarez-Vallina, L., The coming of age of engineered multivalent antibodies, *Drug Discovery Today* (2015), <http://dx.doi.org/10.1016/j.drudis.2015.02.013>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## The coming of age of engineered multivalent antibodies

### Highlights

- 36 out of 39 approved monoclonal antibodies are native full-length IgG
- Antibody engineering may further increase potency and improve the safety profile of conventional antibodies
- Next generation of engineered antibodies may be even more efficient therapeutic molecules
- 18 multivalent engineered antibodies with promising preclinical results are now in clinical trials
- In December 2014, blinatumomab became the first bispecific antibody approved in US.

Download English Version:

<https://daneshyari.com/en/article/10886079>

Download Persian Version:

<https://daneshyari.com/article/10886079>

[Daneshyari.com](https://daneshyari.com)